News and Press Releases
Avallano Strengthens Leadership with New Chief Strategy Officer to Drive AI-Powered Clinical Research Innovation
26 June 2024 -- South Carolina, US -- Avallano, an AI-enabled clinical research company, today announced the appointment of Michael A Ibara PharmD, as chief strategy officer (CSO). Dr Ibara...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: June 26, 2024
X-Chem Strengthens Its Data-Driven Discovery Services
With new CBO appointment industry veteran Paul Davie joins X-Chem executive team to lead strategic growth and partnerships 20 June 2024 -- Massachusetts, US -- Small molecule drug discovery acceleration...
Category: Biotechnology, Drug Discovery, Pharmaceutical
Posted: June 20, 2024
Enterprise Therapeutics appoints Dr Renu Gupta as chief medical officer and Dr Janet Hammond as non-executive director
Appointments bring additional respiratory and late clinical-stage drug development experience as company commences Phase 2a clinical trial of its lead asset 17 June 2024, Brighton, UK -: Enterprise Therapeutics Ltd...
Category: Biotechnology, Pharmaceutical
Posted: June 17, 2024
Sussex Innovation Centre, University of Sussex, Science Park Square, Falmer, Brighton, BN1 9SB, UK
New Kite Clinical Research and Real-World Evidence for Yescarta (Axicabtagene ciloleucel) Demonstrate Benefit From Earlier Lines of Treatment
Analysis shows manufacturing of axicabtagene ciloleucel in second-line treatment of relapsed/refractory large B-cell lymphoma can help reduce time from leukaepheresis to infusion vs third-line plus treatment Data builds on previous...
Category: Biotechnology, Clinical Trials, Drug Discovery
Posted: June 14, 2024
Formycon reports on the results of the annual general meeting
Management provides detailed report on financial year 2023 and current company performance. Shareholders approve all agenda items and formally approve the acts of the members of the management board and...
Category: BioManufacturing
Posted: June 13, 2024
Deep Genomics Expands Executive Leadership and Operations in Latest Strategic Growth Initiative
Company announces executive new hires and marks significant momentum with Cambridge, Massachusetts, US, site opening and Toronto, Canada, office expansion 13 June 2024 -- Massachusetts, US -- Deep Genomics, the...
Category: Biotechnology, Other, Pharmaceutical
Posted: June 13, 2024
480 University Ave, Suite 1300 Toronto, Ontario, Canada, M5G 1V2
Newcells Biotech strengthens executive and US team with key appointments
Dr Valeria Chichagova appointed as director of technology, Dr Colin Brown as chief scientific officer, and Professor Lyle Armstrong as scientific advisor New US commercial appointments also announced to meet...
Category: Biotechnology
Posted: June 11, 2024
Newcells Biotech, The Biophere, Drayman's Way, newcastle Helix, Newcastle-upon-Tyne, NE4 5BX
Kite Receives European Medicines Agency Approval of Safety Monitoring Variation for CAR T-Cell Therapy Portfolio
In-hospital patient monitoring for adverse events reduced from ten to seven days following CAR T-cell therapy infusion 6 June 2024 -- Stockley Park, UK -- Kite, a Gilead Company, today...
Category: Biotechnology, Other, Pharmaceutical
Posted: June 6, 2024
Kite’s TECARTUS (Brexucabtagene Autoelucel) Demonstrates Sustained Overall Survival in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia
After more than four years of follow-up in the pivotal ZUMA-3 study, median overall survival was 26 months and four-year overall survival rate was 40% at 48 months Survival benefit...
Category: Biotechnology, Clinical Trials, Pharmaceutical
Posted: June 3, 2024
Encouraging New Data Presented on Kite’s YESCARTA (Axicabtagene Ciloleucel) for Relapsed/Refractory Central Nervous System Lymphoma
At median follow-up of 24.2 months, no apparent additional risks of adverse events related to axicabtagene ciloleucel were seen Findings also suggest efficacy trend with median progression-free survival and durability...
Category: Biotechnology, Clinical Trials, Pharmaceutical
Posted: June 3, 2024
TMC welcomes Joe Lopez as Chief Financial Officer (CFO) to enhance corporate C-level team
3 June 2024 -- Hampshire, UK -- TMC Pharma Services, an established global product development and clinical research organisation (CRO) headquartered in Hampshire, UK, is pleased to announce the appointment...
Category: Clinical Trials, Pharmaceutical
Posted: June 3, 2024
Lodge Farm Barn Elvetham Park Estate, Fleet Road, Hartley Wintney, Hampshire RG27 8AS, UK
Michael McSorley appointed as new managing director of Origin
3 June 2024 -- Melton, UK -- Global pharmaceutical solutions provider, Origin, has today appointed Michael McSorley as new managing director. Michael McSorley With almost a decade’s experience in the...
Category: Logistics, Manufacturing and Packing
Posted: June 3, 2024
Ardena appoints Jeremie Trochu as Chief Executive Officer
3 June 2024 -- Ghent, Belgium -- Ardena today announces the retirement of Harry Christiaens PhD, and the subsequent appointment of Jeremie Trochu as chief executive officer. Jeremie is a...
Category: BioManufacturing, Biotechnology, Logistics, Manufacturing and Packing, Pharmaceutical
Posted: June 3, 2024
Lykos Therapeutics Appoints Finance Veteran Scott Giacobello to the Board of Directors
30 May 2024 -- California, US -- Lykos Therapeutics, a company dedicated to transforming mental healthcare, announced the appointment of finance veteran Scott Giacobello to the company's Board of Directors, effective immediately. A...
Category: Biotechnology, Clinical Trials, Other
Posted: May 30, 2024
KITE Shares New Data at EHA 2024 Which Demonstrates Positive Patient Outcomes and Advances in Delivery of CAR T-Cell Therapy
Analysis comparing real-world and clinical trial data shows Yescarta (Axicabtagene Ciloleucel) has higher manufacturing success rates and improved T-cell performance, respectively, in second-line vs third-line+ treatment of large B-cell lymphoma...
Category: Clinical Trials, Pharmaceutical
Posted: May 14, 2024
